All In MedTech

FDA Clearance Tracker · P250026

Atellica IM free PSA II (fPSAII)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 11, 2026

Approved

Time to decision

297 days

Received Jul 18, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250026
Device name
Atellica IM free PSA II (fPSAII)
Applicant location
Tarrytown, NY
Received
Jul 18, 2025
Decided
May 11, 2026
Decision
Approved

Device type

Device class
Class III

Every decision under product code MTG

FDA's approval statement

As written in FDA's record.

Approval for the Atellica IM free PSA II (fPSAII):The Atellica IM free PSA II (fPSAII) assay is for in vitro diagnostic use in the quantitative measurement of free prostate-specific antigen (fPSA) in human serum and plasma (lithium heparin and EDTA) using the Atellica IM Analyzer. The Atellica IM fPSAII assay is intended to be used in conjunction with the Atellica IM total PSA II (tPSAII) assay in men aged 50 years and older with total prostate-specific antigen (PSA) values between 4 ng/mL (µg/L) and 10 ng/mL (µg/L) and a digital rectal examination (DRE) non-suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease. A prostate biopsy is required for the diagnosis of prostate cancer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.